Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation

Apoptosis

Volumn 20, Issue 4, 2015, Pages 535-550

  Bonnefond, Marie Laure ^a,b,c   Lambert, Bernard ^a,b,c,d   Giffard, Florence ^a,b,c   Abeilard, Edwige ^a,b,c   Brotin, Emilie ^a,b,c   Louis, Marie Hélène ^a,b,c   Gueye, Mor Sény ^a,b,c   Gauduchon, Pascal ^a,b,c   Poulain, Laurent ^a,b,c   N'Diaye, Monique ^a,b,c  

^a NORMANDIE UNIVERSITÉ   (France)

^b INSERM   (France)

^c Francois Baclesse Comprehensive Cancer Centre   (France)

^d Délégation régionale Ile de France Est   (France)

Author keywords

Calcium signal; Calmodulin; Mcl 1; mTOR; Ovarian cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; BORTEZOMIB; CALCIUM; CALCIUM CHELATING AGENT; CALMODULIN; CALMODULIN INHIBITOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA; BCL2L1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHELATION; CHEMOSENSITIZATION; CYTOSTASIS; DOWN REGULATION; GENETIC TRANSFECTION; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; ANTAGONISTS AND INHIBITORS; CARCINOMA; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOPHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BCL-X PROTEIN; CALCIUM; CALCIUM SIGNALING; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OVARIAN NEOPLASMS;

EID: 84925491085     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1095-3     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674 10.1016/j.cell.2011.02.013 1:CAS:528:DC%2BC3MXjsFeqtrk%3D 21376230
2. Juin P, Geneste O, Gautier F, Depil S, Campone M (2013) Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 13:455-465 10.1038/nrc3538 1:CAS:528:DC%2BC3sXps1Ghur4%3D 23783119
3. Shigemasa K, Katoh O, Shiroyama Y et al (2002) Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 93:542-550 10.1111/j.1349-7006.2002.tb01289.x 1:CAS:528:DC%2BD38XlsVGht7Y%3D 12036450
4. Villedieu M, Louis MH, Dutoit S et al (2007) Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 105:31-44 10.1016/j.ygyno.2006.12.011 1:CAS:528:DC%2BD2sXjsVemsbg%3D 17275076
5. Brotin E, Meryet-Figuiere M, Simonin K et al (2010) Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int.J. Cancer 126:885-895 1:CAS:528:DC%2BD1MXhs1SqsLrI
6. Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681 10.1038/nature03579 1:CAS:528:DC%2BD2MXks1Ogtb0%3D 15902208
7. van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399 10.1016/j.ccr.2006.08.027 2953559 17097561
8. Simonin K, N'diaye M, Lheureux S et al (2013) Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 18:492-508 10.1007/s10495-012-0799-x 1:CAS:528:DC%2BC3sXksF2ksLc%3D 23344663
9. Konopleva M, Milella M, Ruvolo P et al (2012) MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 26:778-787 10.1038/leu.2011.287 3604791 1:CAS:528:DC%2BC38XlsFSnsbY%3D 22064351
10. Jebahi A, Villedieu M, Petigny C et al (2014) PI3 K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-x-targeting strategies, provided that Bim expression is induced. Cancer Lett
11. Carracedo A, Baselga J (2008) Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7:3805-3809 10.4161/cc.7.24.7244 3130531 1:CAS:528:DC%2BD1MXhvVSitro%3D 19098454
12. Prevarskaya N, Skryma R, Shuba Y (2013) Targeting Ca(2)(+) transport in cancer: close reality or long perspective? Expert Opin Ther Targets 17:225-241 10.1517/14728222.2013.741594 1:CAS:528:DC%2BC3sXislOnur0%3D 23294334
13. Yang SL, Cao Q, Zhou KC, Feng YJ, Wang YZ (2009) Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene 28:1320-1328 10.1038/onc.2008.475 1:CAS:528:DC%2BD1MXntFKjtA%3D%3D 19151765
14. Wilson BE, Mochon E, Boxer LM (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16:5546-5556 231554 1:CAS:528:DyaK28XlvFamur4%3D 8816467
15. Davis FM, Azimi I, Faville RA et al (2013) Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene
16. Jiang CC, Lucas K, Avery-Kiejda KA et al (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68:6708-6717 10.1158/0008-5472.CAN-08-0349 1:CAS:528:DC%2BD1cXpslKmsLo%3D 18701495
17. Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB (2010) KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol Ther 9:224-235 10.4161/cbt.9.3.10747 1:CAS:528:DC%2BC3cXpt1Omsr4%3D 20023417
18. Thomas LW, Lam C, Edwards SW (2010) Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981-2989 10.1016/j.febslet.2010.05.061 1:CAS:528:DC%2BC3cXosVyhu7s%3D 20540941
19. Mills JR, Hippo Y, Robert F et al (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853-10858 10.1073/pnas.0804821105 2504845 1:CAS:528:DC%2BD1cXpvFOju7c%3D 18664580
20. Ballou LM, Jiang YP, Du G, Frohman MA, Lin RZ (2003) Ca(2 +)- and phospholipase D-dependent and -independent pathways activate mTOR signaling. FEBS Lett 550:51-56 10.1016/S0014-5793(03)00816-0 1:CAS:528:DC%2BD3sXmsVKnsbY%3D 12935885
21. Berchtold MW, Villalobo A (2014) The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Biochim Biophys Acta 1843:398-435 10.1016/j.bbamcr.2013.10.021 1:CAS:528:DC%2BC2cXlt1Wr 24188867
22. Hsieh AC, Costa M, Zollo O et al (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249-261 10.1016/j.ccr.2010.01.021 2901095 1:CAS:528:DC%2BC3cXlsVWqtLY%3D 20227039
23. Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S (2013) Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J Biol Chem 288:35287-35296 10.1074/jbc.M113.495986 3853277 1:CAS:528:DC%2BC3sXhvFWrsLjL 24133218
24. Lucas KM, Mohana-Kumaran N, Lau D et al (2012) Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18:783-795 10.1158/1078-0432.CCR-11-1166 1:CAS:528:DC%2BC38XhslOktbY%3D 22173547
25. Hahnel PS, Thaler S, Antunes E, Huber C, Theobald M, Schuler M (2008) Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68:3899-3906 10.1158/0008-5472.CAN-07-6286 18483275
26. Ma S, Yang Y, Wang C et al (2009) Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphatidylinositide 3-kinase/Akt/HDM2 pathway. J Biol Chem 284:24773-24782 10.1074/jbc.M109.028621 2757181 1:CAS:528:DC%2BD1MXhtV2nsLjP 19586909
27. Deb TB, Coticchia CM, Dickson RB (2004) Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem 279:38903-38911 10.1074/jbc.M405314200 1:CAS:528:DC%2BD2cXnt1yjsL4%3D 15247222
28. Breuleux M, Klopfenstein M, Stephan C et al (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3 K/mTOR inhibition. Mol Cancer Ther 8:742-753 10.1158/1535-7163.MCT-08-0668 3440776 1:CAS:528:DC%2BD1MXks1amsb8%3D 19372546
29. Feldman ME, Apsel B, Uotila A et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38 10.1371/journal.pbio.1000038 19209957
30. Carracedo A, Ma L, Teruya-Feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3 K-dependent feedback loop in human cancer. J Clin Invest 118:3065-3074 2518073 1:CAS:528:DC%2BD1cXhtV2isb3P 18725988
31. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293 10.1016/j.cell.2012.03.017 3331679 1:CAS:528:DC%2BC38Xls1eguro%3D 22500797
32. Fruman DA, Rommel C (2014) PI3 K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140-156 10.1038/nrd4204 3994981 1:CAS:528:DC%2BC2cXhs1SnsLc%3D 24481312
33. Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211 10.1080/07853890600551037 1:CAS:528:DC%2BD28XktVyms7c%3D 16720434
34. Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277:2-21 10.1111/j.1742-4658.2009.07366.x 1:CAS:528:DC%2BC3cXhs1Gntw%3D%3D 19843174
35. Denoyelle C, Lambert B, Meryet-Figuiere M et al (2014) miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis 5:e1445 10.1038/cddis.2014.389 1:CAS:528:DC%2BC2cXhslGjsL7L 25299770
36. Conus NM, Hemmings BA, Pearson RB (1998) Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. J Biol Chem 273:4776-4782 10.1074/jbc.273.8.4776 1:CAS:528:DyaK1cXhtlSqs7c%3D 9468542
37. Thomas A, Pepper C, Hoy T, Bentley P (2004) Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 45:997-1008 10.1080/10428190310001639470 1:CAS:528:DC%2BD2cXjtFOjsLk%3D 15291360
38. Rutherford C, Childs S, Ohotski J et al (2013) Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death Dis 4:e927 10.1038/cddis.2013.455 3847331 1:CAS:528:DC%2BC3sXhvVGgsLnM 24263101
39. Gulati P, Gaspers LD, Dann SG et al (2008) Amino acids activate mTOR complex 1 via Ca2 +/CaM signaling to hVps34. Cell Metab 7:456-465 10.1016/j.cmet.2008.03.002 2587347 1:CAS:528:DC%2BD1cXmtFeiurg%3D 18460336
40. Dong B, Valencia CA, Liu R (2007) Ca(2 +)/calmodulin directly interacts with the pleckstrin homology domain of AKT1. J Biol Chem 282:25131-25140 10.1074/jbc.M702123200 1:CAS:528:DC%2BD2sXpt1Sltb8%3D 17580302
41. Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD (2009) Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat 115:545-560 10.1007/s10549-008-0097-z 3736740 1:CAS:528:DC%2BD1MXmsVCrtbw%3D 18587642
42. Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A (2013) TRP channels: diagnostic markers and therapeutic targets for breast cancer? Trends Mol Med 19:117-124 10.1016/j.molmed.2012.11.004 1:CAS:528:DC%2BC3sXitVGjtb8%3D 23253476
43. Stewart TA, Yapa KT, Monteith GR (2014) Altered calcium signaling in cancer cells. Biochim Biophys, Acta
44. Dubois C, Vanden Abeele F, Lehen'kyi V et al (2014) Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer. Cancer Cell 26:19-32 10.1016/j.ccr.2014.04.025 1:CAS:528:DC%2BC2cXhtVams7rK 24954132
45. Prevarskaya N, Ouadid-Ahidouch H, Skryma R, Shuba Y (2014) Remodelling of Ca2 + transport in cancer: how it contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol Sci 369:20130097
46. Lehen'kyi V, Raphael M, Prevarskaya N (2012) The role of the TRPV6 channel in cancer. J Physiol 590:1369-1376 10.1113/jphysiol.2011.225862 3382328 22331416
47. Li W, Zhang SL, Wang N, Zhang BB, Li M (2011) Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation. Cancer Invest 29:339-346 10.3109/07357907.2011.568565 1:CAS:528:DC%2BC3MXmtl2htL4%3D 21438841
48. Dziegielewska B, Gray LS, Dziegielewski J (2014) T-type calcium channels blockers as new tools in cancer therapies. Pflug Arch 466:801-810 10.1007/s00424-014-1444-z 1:CAS:528:DC%2BC2cXht1Cjsbg%3D